Key Interview: Ganeden Looks for Probiotic Opportunities Beyond Digestive Health


09 Jun 2017 --- Consumers increasingly self-diagnose and experiment with diets that they believe will improve gut health. These personalized diets are creating new opportunities for free from and fortification. Innova Market Insights has reported +25% CAGR from 2012 to 2016 for food & beverage launches with a digestive health positioning, with probiotics benefiting. In fact there was a +30% CAGR in new products featuring the word “probiotic” during this period, despite the term currently not being allowed in EU markets.

“Globally, the probiotic industry continues to grow and impress. There’s more and more evidence coming out showing additional uses for probiotics – not just general uses, but more specific uses, such as strains that work specifically for kidney health, or strains that are being studied for cardiovascular health, or cholesterol,” says Michael Bush, President & CEO of probiotic ingredient supplier Ganeden, and also Executive Board President of the International Probiotics Association. “So globally, as an industry and as a trade association, we are very encouraged by the work being done clinically as well as the market acceptance, support and ongoing growth in the industry everywhere we go.” In a detailed interview with NutritionInsight he discusses challenges and opportunities in the probiotic market and their latest innovations.

Ganeden continues to pave the way for scientific advancements and research in the probiotic ingredient space. The international leader in probiotic technology announced that two recent studies have been published in peer-reviewed journals, bringing the total number to 26. The research shows that Ganeden’s patented, shelf-stable probiotic strain, GanedenBC30 (Bacillus coagulans GBI-30, 6086), provides added benefits when combined with other functional ingredients such as plant proteins or HMB (beta-hydroxy-beta-methylbutyrate).

Click to EnlargeGaneden has also used its patented probiotic strain to develop an immune health ingredient: Staimune. The new ingredient utilizes the cell of the probiotic GanedenBC30 to support immune health, at cost effective inclusion levels. Available later this summer, Ganeden anticipates Staimune to be an industry-changing development.

Officially identified as “Inactivated Bacillus coagulans GBI-30, 6086,” Staimune’s ease of formulation opens up new opportunities in functional foods and beverages – most importantly in shelf-stable beverages and high-water-activity products. Staimune is FDA GRAS, non-GMO, organic compliant and kosher, making it extremely accessible for use in a vast amount of applications. 

Staimune provides the option for manufacturers that want to focus specifically on immune health, and for those with processes that cause formulation challenges for live probiotics. With an inclusion rate of just 50mg, Staimune does not alter the flavor or texture profiles of finished goods. This allows for easy application into a large number of product categories. Staimune will be available for formulation starting in the summer of 2017.

“We see the market from a global perspective continuing to grow at a rate of +7% each year. As the probiotic market evolves and matures and goes beyond just digestive health, we’re starting to see opportunities in the immune health space. The immune market is one that is pretty robust, so we’ve recently launched a new ingredient that is the inactivated cells of our probiotic. It’s not actually a probiotic, but is derived from the probiotic and has been shown to provide immune benefits.”

“The cells in Staimune are no longer alive, so one benefit is that the ingredient can be formulated into  products where probiotics simply can’t go. GanedenBC30 is shelf stable, but for various reasons, it can’t survive in certain products such as shelf stable beverages or high-water-activity products. Staimune allows us to enter into new markets that we’ve never been able to enter before, especially internationally where refrigerated shipping is not the norm,” he says. Bush notes a good deal of interest from CPG companies in the new ingredient already, so we can expect to see products with Staimune in the next quarter.

Click to EnlargeBush notes that the company has done a great deal of work in getting GanedenBC30 approved, and since these are the inactivated cells of the strain, there are no regulatory barriers standing in the way. “It's received FDA GRAS status in the US, and the organism itself is already approved for use in most countries around the world,” he notes. “To put it into perspective, two years ago we shipped to four or five countries and this year, as of the end of May, we've shipped to 48 countries.”

Are there no marketing challenges involved in promoting a product made from dead cells though? “From a consumer understanding perspective, inactivated cells are pretty common in various parts of the world. We believe there will be some learning curve there, but we don't see it as a hurdle that's insurmountable. We have lots of IP around this space, so we're in pretty good shape,” he replies.

But what about other market opportunities for the company’s products? For Bush, most really revolve around the clinical work they’re doing. “Over the last several years, we have conducted 10-12 sports nutrition studies looking at things like protein utilization, muscle recovery and power output. And those studies have now allowed us to support a protein utilization claim with GanedenBC30,” he explains. “So our various science innovations have really been the market opportunity drivers for us. We like to stay ahead of the curve and make sure we have solid ongoing science. The studies we do obviously help us support claims and market strategies. Rather than just coming up with new ideas, we  vet the research first. Once it is proven, then we go to market with new ingredients or claims.”

And what about Ganeden’s expansion plans going forward? “We continue to explore a variety of growth avenues. Business is growing at an exceptional rate and has been for a number of years. At this point, we have a variety of options on the table; whether it’s adding new ingredients to the portfolio or additional team members.We've started our international expansion by placing Ganeden staff members in China, Thailand and Mexico, and we will more than likely be adding some in Europe within the next 12 months,” he says. 

Ganeden’s ingredient business came into being in 2008 and it’s been right on track all along. “We’ve been doubling in size every two years and we see that continuing. The US market is our strongest at this point, but  the Asian market has also been growing very quickly; Japan, China and India are all looking positive for us with many opportunities; so we are looking forward to continually expand that business,” he concludes.

A detailed interview with Michael Bush will appear in the July/August issue of The World of Food Ingredients

By Robin Wyers & Lucy Gunn

To contact our editorial team please email us at

Ganeden, Inc.


Founded in 1997, Ohio-based Ganeden is at the forefront of probiotic research and product development with an extensive library of published studies and more than 130 patents for probiotic technologies for the supplement, food, beverage, animal health, sports nutrition and personal care ingredients markets. Ganeden is best known for GanedenBC30® its patented, FDA GRAS, highly stable probiotic ingredient. Through the fermentation process of GanedenBC30®, Ganeden developed Bonicel®, the first science-backed, probiotic-derived, personal care ingredient shown to dramatically reduce signs of aging. Ganeden’s newest ingredient, Staimune™ is patented probiotic technology comprising of inactivated GanedenBC30® which has been shown to have immune benefits.  Ganeden is more than an ingredient supplier; Ganeden works with its clients as a partner, taking special care to add value from initial contact to product launch and beyond. For more information about Ganeden and licensing opportunities visit

Introducing GanedenBC30® (Bacillus coagulans GBI-30, 6086), Ganeden’s patented probiotic ingredient that can be found in more than 750 leading food, beverage, sports nutrition and companion animal products around the world. Unlike most other probiotic strains, GanedenBC30® is a spore-former which makes it highly stable and allows it to remain viable through most manufacturing processes, three years of shelf life and the low pH of stomach acid.  The benefits, safety and efficacy of GanedenBC30® is backed by over 20 published studies and FDA GRAS status from the United States FDA. It can be formulated into virtually any food, beverage, sports nutrition or companion animal product that is baked, boiled, frozen or squeezed…. including all hot or refrigerated beverages!  For more information, please visit

Related Articles

Nutrition & Health News

Plant-based possibilities: Report details novel sugar replacements for beverages

19 Apr 2018 --- PreScouter, a Chicago based technology scouting company, details novel replacements for sugars in a new analysis, that are from natural sources, safe, technologically viable and environmentally stable, for use in beverages. The company hopes that the report answers consumer calls for sweeteners that are both natural and healthy, in light of diabetes and obesity epidemics, and that it may aid informing beverage providers on how to best respond to calls for lowering sugar levels in drinks.

Nutrition & Health News

Probiotic peanut allergy treatment: Chr. Hansen enters new partnership

18 Apr 2018 --- Probiotic strain, LGG, can potentially play a part in peanut allergy treatment. Prota Therapeutics, developer of oral immunotherapies to treat food allergies, has partnered with Chr. Hansen, Danish food ingredients producer, to assess LGG in a clinical trial to develop a treatment for the allergy. Chr. Hansen tells NutritionInsight that the partnership is in effect as from today, and strengthens the position of Chr. Hansen in a market expected to grow to €10billion by 2025.

Nutrition & Health News

Anlit launches “fun and tasty” omega 3 chew for pregnant women

18 Apr 2018 --- Producers of high-quality children’s dietary supplements, Anlit, have launched "tasty", high-DHA omega 3 chewable supplements for pregnant and breastfeeding women. 

Nutrition & Health News

Bone loss prevention: Probi targets new platform for probiotic products

11 Apr 2018 --- Probi has released new clinical results with strong evidence of Probi probiotic supplements significantly reducing bone loss in post-menopausal women. This signifies the possible development of a new probiotic concept within the arena of bone health and osteoporosis.

Nutrition & Health News

Gut-brain axis: NZMP SureStart joins research program to aid infant formula development

09 Apr 2018 --- NZMP SureStart, the global B2B pediatric ingredients brand of Fonterra, has joined Smarter Lives, a five-year research program that investigates how nutrition impacts the gut-brain axis. Smarter Lives is funded by New Zealand’s Ministry of Business, Innovation and Employment and led by New Zealand research institute, AgResearch. It will investigate how foods influence brain function via the sophisticated communication systems between the gut and the brain.

More Articles